Zevra Therapeutics (ZVRA) News Today → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free ZVRA Stock Alerts $4.73 -0.03 (-0.63%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 1:24 AM | americanbankingnews.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasted to Post Q2 2024 Earnings of ($0.46) Per ShareMay 15 at 7:02 AM | marketbeat.comResearch Analysts Set Expectations for Zevra Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ZVRA)Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Stock analysts at William Blair decreased their Q2 2024 earnings estimates for Zevra Therapeutics in a report released on Monday, May 13th. William Blair analyst T. Lugo now forecasts that the company will earn ($0.46) per share for the quartMay 11, 2024 | americanbankingnews.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Expected to Earn Q2 2024 Earnings of ($0.44) Per ShareMay 10, 2024 | marketbeat.comZevra Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.44) Per Share, Roth Capital Forecasts (NASDAQ:ZVRA)Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Investment analysts at Roth Capital boosted their Q2 2024 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research note issued on Wednesday, May 8th. Roth Capital analyst J. Aschoff now anticipates that the company wiMay 10, 2024 | americanbankingnews.comFY2027 EPS Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Boosted by Roth CapitalMay 9, 2024 | finance.yahoo.comZevra Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 9, 2024 | finance.yahoo.comZevra Therapeutics to Participate at Upcoming Investor EventsMay 9, 2024 | marketbeat.comFY2027 EPS Estimates for Zevra Therapeutics, Inc. Increased by Analyst (NASDAQ:ZVRA)Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Research analysts at Roth Capital increased their FY2027 earnings per share estimates for shares of Zevra Therapeutics in a research note issued on Wednesday, May 8th. Roth Capital analyst J. Aschoff now expects that the company will post earMay 9, 2024 | finance.yahoo.comZevra Therapeutics Inc (ZVRA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 8, 2024 | finance.yahoo.comZevra Therapeutics Inc (ZVRA) Q1 2024 Earnings: Misses EPS Estimates, Revenue Consistent with ...May 8, 2024 | investorplace.comZVRA Stock Earnings: Zevra Therapeutics Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comZevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate UpdatesMay 6, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAMay 2, 2024 | marketbeat.comZevra Therapeutics (ZVRA) to Release Quarterly Earnings on WednesdayZevra Therapeutics (NASDAQ:ZVRA) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports.May 1, 2024 | globenewswire.comZevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024April 29, 2024 | finance.yahoo.comZevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024April 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAApril 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAApril 15, 2024 | globenewswire.comZevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual MeetingApril 12, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAApril 10, 2024 | globenewswire.comZevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit FacilityApril 10, 2024 | globenewswire.comZevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit FacilityApril 6, 2024 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Buy" by AnalystsShares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have earned a consensus rating of "Buy" from the six analysts that are currently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month price objective among brokApril 5, 2024 | marketbeat.comHC Wainwright Brokers Lift Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Research analysts at HC Wainwright raised their Q1 2024 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a report issued on Wednesday, April 3rd. HC Wainwright analyst O. Livnat now expects that the company will earn ($0April 4, 2024 | finance.yahoo.comZevra Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsApril 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAApril 4, 2024 | marketbeat.comHC Wainwright Brokers Cut Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Stock analysts at HC Wainwright reduced their FY2025 earnings estimates for Zevra Therapeutics in a research note issued on Wednesday, April 3rd. HC Wainwright analyst O. Livnat now expects that the company will post earnings per share of $0.April 3, 2024 | markets.businessinsider.comZevra Therapeutics: Poised for Transformation and Growth Amidst Market OverreactionApril 3, 2024 | finance.yahoo.comBearish: Analysts Just Cut Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Revenue and EPS estimatesApril 3, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Zevra Therapeutics (NASDAQ:ZVRA)HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday.April 3, 2024 | marketbeat.comRoth Capital Analysts Lower Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities research analysts at Roth Capital cut their Q1 2024 EPS estimates for shares of Zevra Therapeutics in a research note issued to investors on Sunday, March 31st. Roth Capital analyst J. Aschoff now forecasts that the company will earnApril 2, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAApril 2, 2024 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $18.00 at Maxim GroupMaxim Group lifted their target price on shares of Zevra Therapeutics from $12.00 to $18.00 and gave the company a "buy" rating in a report on Tuesday.April 2, 2024 | marketbeat.comEquities Analysts Set Expectations for Zevra Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:ZVRA)Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at Roth Capital dropped their FY2028 EPS estimates for shares of Zevra Therapeutics in a research report issued on Sunday, March 31st. Roth Capital analyst J. Aschoff now forecasts that the company will earn $2.35 per share for the yApril 1, 2024 | insidermonkey.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Call TranscriptApril 1, 2024 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Receives Overweight Rating from Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating on shares of Zevra Therapeutics in a research report on Monday.March 31, 2024 | finance.yahoo.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported, And Analysts Assigned A US$18.25 Price TargetMarch 30, 2024 | seekingalpha.comZevra Therapeutics, Inc. (ZVRA) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | marketbeat.comWilliam Blair Research Analysts Decrease Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at William Blair cut their FY2024 earnings per share estimates for shares of Zevra Therapeutics in a research note issued on Wednesday, March 27th. William Blair analyst T. Lugo now anticipates that the company will earn ($1.50) perMarch 28, 2024 | investorplace.comZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023March 28, 2024 | benzinga.comZevra Therapeutics: Q4 Earnings InsightsMarch 28, 2024 | globenewswire.comZevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdatesMarch 27, 2024 | benzinga.comEarnings Outlook For Zevra TherapeuticsMarch 26, 2024 | globenewswire.comZevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic HypersomniaMarch 25, 2024 | globenewswire.comZevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 19, 2024 | finance.yahoo.comKemPharm Inc (1GDA.DU)March 18, 2024 | globenewswire.comZevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024March 14, 2024 | finance.yahoo.comZevra Therapeutics (NASDAQ:ZVRA) investors are sitting on a loss of 81% if they invested five years agoMarch 12, 2024 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated at William BlairWilliam Blair initiated coverage on Zevra Therapeutics in a report on Tuesday. They issued an "outperform" rating for the company.March 12, 2024 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of "Buy" from BrokeragesZevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has been assigned an average rating of "Buy" from the five brokerages that are currently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation. The average 1 year price target Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. ZVRA Media Mentions By Week ZVRA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZVRA News Sentiment▼0.150.52▲Average Medical News Sentiment ZVRA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZVRA Articles This Week▼72▲ZVRA Articles Average Week Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Trevi Therapeutics News Incannex Healthcare News Atossa Therapeutics News Conduit Pharmaceuticals News Inventiva News Organigram News Acrivon Therapeutics News Werewolf Therapeutics News Telomir Pharmaceuticals News Veru News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZVRA) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceThe Presidential candidate you should REALLY be worried aboutStansberry ResearchProtect Your Bank Account Before It’s Too LateWeiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressWhat’s Really Next for America…Porter & CompanyHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
